JP2020525451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525451A5 JP2020525451A5 JP2019571328A JP2019571328A JP2020525451A5 JP 2020525451 A5 JP2020525451 A5 JP 2020525451A5 JP 2019571328 A JP2019571328 A JP 2019571328A JP 2019571328 A JP2019571328 A JP 2019571328A JP 2020525451 A5 JP2020525451 A5 JP 2020525451A5
- Authority
- JP
- Japan
- Prior art keywords
- bbb
- permeable
- optionally
- epichaperome
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940123411 Epichaperome inhibitor Drugs 0.000 claims 19
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 11
- 230000009529 traumatic brain injury Effects 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical group C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 206010057315 Daydreaming Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000006550 Mydriasis Diseases 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001760 anti-analgesic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 229940025708 injectable product Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 230000004382 visual function Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524452P | 2017-06-23 | 2017-06-23 | |
| US62/524,452 | 2017-06-23 | ||
| US201762532989P | 2017-07-14 | 2017-07-14 | |
| US62/532,989 | 2017-07-14 | ||
| PCT/US2018/038893 WO2018237211A2 (en) | 2017-06-23 | 2018-06-22 | Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525451A JP2020525451A (ja) | 2020-08-27 |
| JP2020525451A5 true JP2020525451A5 (enExample) | 2021-08-05 |
Family
ID=64737388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571328A Pending JP2020525451A (ja) | 2017-06-23 | 2018-06-22 | 外傷性脳損傷及びその後遺症のためのエピシャペローム阻害剤療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210161902A1 (enExample) |
| EP (1) | EP3641751A4 (enExample) |
| JP (1) | JP2020525451A (enExample) |
| KR (1) | KR20200019220A (enExample) |
| CN (1) | CN111683658A (enExample) |
| AU (1) | AU2018290288A1 (enExample) |
| CA (1) | CA3068274A1 (enExample) |
| IL (1) | IL271387A (enExample) |
| TW (1) | TW201919613A (enExample) |
| WO (1) | WO2018237211A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3061185A1 (en) * | 2017-04-24 | 2018-11-01 | Samus Therapeutics, Inc. | Hsp90 inhibitor oral formulations and related methods |
| WO2023097071A2 (en) * | 2021-11-29 | 2023-06-01 | The Regents Of The University Of California | Methods for treating traumatic brain injury |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2645095T3 (es) * | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| KR101906568B1 (ko) * | 2009-10-07 | 2018-10-10 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체 |
| US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
| KR102010222B1 (ko) * | 2011-04-05 | 2019-08-13 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｓｐ９０ 억제제 |
| CA3061185A1 (en) * | 2017-04-24 | 2018-11-01 | Samus Therapeutics, Inc. | Hsp90 inhibitor oral formulations and related methods |
-
2018
- 2018-06-22 AU AU2018290288A patent/AU2018290288A1/en not_active Abandoned
- 2018-06-22 CA CA3068274A patent/CA3068274A1/en active Pending
- 2018-06-22 EP EP18819818.8A patent/EP3641751A4/en not_active Withdrawn
- 2018-06-22 WO PCT/US2018/038893 patent/WO2018237211A2/en not_active Ceased
- 2018-06-22 KR KR1020207001656A patent/KR20200019220A/ko not_active Withdrawn
- 2018-06-22 JP JP2019571328A patent/JP2020525451A/ja active Pending
- 2018-06-22 CN CN201880052529.4A patent/CN111683658A/zh active Pending
- 2018-06-22 TW TW107121514A patent/TW201919613A/zh unknown
- 2018-06-22 US US16/624,274 patent/US20210161902A1/en not_active Abandoned
-
2019
- 2019-12-12 IL IL271387A patent/IL271387A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519404A5 (enExample) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| PH12021551635A1 (en) | Hexone glucokinase inhibitor and use thereof | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2015523407A5 (enExample) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| RU2010150478A (ru) | Способы профилактики и лечения нейродегенеративных заболеваний | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2016147915A5 (enExample) | ||
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| HRP20191029T1 (hr) | Derivati morfinana radi liječenja predoziranja lijekom | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2018507243A5 (enExample) | ||
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| MY207397A (en) | Pharmaceutical composition comprising sglt-2 inhibitor and dpp-iv inhibitor | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| JP2020525451A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2009131745A (ru) | Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors |